GPR35

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Friday, November 24, 2023

GSK4381406 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.

Key Points: 
  • GSK4381406 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.
  • GSK becomes eligible for a low single digit royalty from Sosei Heptares on net sales of GSK4381406 should it become commercially available.
  • Sosei Heptares’ strategy is to advance novel or best-in-class products through early clinical development before seeking a partner to develop and commercialize in major markets.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “We are delighted at the prospect of regaining ownership of GSK4381406 from GSK.

ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program for Treatment of Gastrointestinal Disease and Cancers

Retrieved on: 
Wednesday, September 13, 2023

OXFORD, England, Sept. 13, 2023 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK's innovation agency. The grant, for a total of £495,000 (~$625,000), will fund research designed to enable the company to conduct translational studies of first-in-class GPR35 inhibitors for the treatment of gastrointestinal inflammatory diseases and cancers, ultimately allowing for the advancement of those compounds into clinical development.

Key Points: 
  • The project is focused on optimising first-of-their-kind rodent-GPR35 antagonist small molecules to support preclinical evaluation of opportunities for GPR35 inhibitors in clinically translational murine models of disease.
  • The role of GPR35 in GI diseases is genetically validated with several drug developers advancing programs designed to address the target.
  • This includes research showing that GPR35 variants are linked to inflammatory bowel disease, and that GPR35 expression is upregulated in GI cancers.
  • Furthermore, study results have demonstrated that commonly dysregulated GI-cancer genes can be reversed by knocking out GPR35 in cancer cells.

ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Thursday, March 30, 2023

OXFORD, United Kingdom, March 30, 2023 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023. The presentation will include a suite of preclinical data highlighting the biological role of GPR35 in GI disease and cancers, outlining the hypothesis that GPR35 activity has the potential to drive pro-oncogenic growth biology in digestive tract cancers, and spotlighting the company's discovery of potent GPR35 inhibitors that demonstrate the ability to prevent GPR35 signaling and tumour growth in a patient-derived cancer model. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • ThirtyFiveBio, which has raised $20 million in seed financing to date, was created in 2021 by M:M Bio Limited (M:M Bio) in partnership with Canaan Partners.
  • Supporting the company's focus on GPR35 inhibition is a collection of pre-clinical data generated by its scientists that highlights the association between GPR35 mutations and GI diseases.
  • This includes research showing that GPR35 variants are linked to irritable bowel disease, and that GPR35 expression is upregulated in GI cancers.
  • Furthermore, study results have demonstrated that commonly dysregulated GI-cancer genes can be reversed by knocking out GPR35 in cancer cells.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2021

Retrieved on: 
Thursday, February 10, 2022

TOKYO and CAMBRIDGE, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (the Company; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2021.

Key Points: 
  • TOKYO and CAMBRIDGE, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (the Company; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2021.
  • Sosei Heptares regained worldwide rights to this program from AbbVie in January 2021.
  • Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).
  • Sosei, Heptares, the logo and StaR are trademarks of Sosei Group companies.

Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System

Retrieved on: 
Monday, December 21, 2020

Under the agreement, GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR technology and structure-based drug design (SBDD) platform.

Key Points: 
  • Under the agreement, GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR technology and structure-based drug design (SBDD) platform.
  • Sosei Heptares and GSK will collaborate on research and early preclinical development and GSK will lead clinical development, manufacturing and commercialization.
  • In addition, Sosei Heptares will be eligible to receive tiered, royalties on net sales of products resulting from the collaboration.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).